Skip to content

Cellectar Biosciences, Inc.: 10-Q filed 2013-08-12

What Cellectar Biosciences, Inc. reported in its quarterly report filed 2013-08-12 (fiscal Q2 2013): 27 published measures, 88 facts as tagged in accession 0001144204-13-044768.

This filing

Form
10-Q (quarterly report)
Filed
2013-08-12
Fiscal period
fiscal Q2 2013
Accession
0001144204-13-044768 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Cellectar Biosciences, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-06-3012,125,037USD
At 2012-12-3111,478,164USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-06-306,681,102USD
At 2012-12-311,319,789USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-06-305,443,935USD
At 2012-12-3110,158,375USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-06-305,828,253USD
At 2012-12-314,677,545USD
At 2012-06-307,146,400USD
At 2011-12-315,505,960USD
At 2002-11-060USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-04-01 to 2013-06-30-2,064,462USD91
2013-01-01 to 2013-06-30-5,518,341USD181
2002-11-07 to 2013-06-30-45,795,741USD3889
2012-04-01 to 2012-06-30-2,230,811USD91
2012-01-01 to 2012-06-30-4,587,714USD182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-06-30-3,922,597USD181
2002-11-07 to 2013-06-30-35,640,327USD3889
2012-01-01 to 2012-06-30-3,200,300USD182

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2013-01-01 to 2013-06-3092,977USD181
2002-11-07 to 2013-06-305,677,260USD3889
2012-01-01 to 2012-06-3029,140USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-01-01 to 2013-06-305,044,514USD181
2002-11-07 to 2013-06-3048,186,094USD3889
2012-01-01 to 2012-06-304,869,880USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-01-01 to 2013-06-3028,791USD181
2002-11-07 to 2013-06-30-6,717,514USD3889
2012-01-01 to 2012-06-30-29,140USD182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-06-302,513,499USD
At 2012-12-312,645,003USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-04-01 to 2013-06-30377,893USD91
2013-01-01 to 2013-06-30803,791USD181
2002-11-07 to 2013-06-305,161,961USD3889
2012-04-01 to 2012-06-30406,122USD91
2012-01-01 to 2012-06-30823,475USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-04-01 to 2013-06-30-2,722,587USD91
2013-01-01 to 2013-06-30-5,434,902USD181
2002-11-07 to 2013-06-30-45,456,470USD3889
2012-04-01 to 2012-06-30-2,211,504USD91
2012-01-01 to 2012-06-30-4,537,489USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-06-306,030,622USD
At 2012-12-315,130,477USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-06-306,090,876USD
At 2012-12-31732,691USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2013-06-301,675,462USD
At 2012-12-311,675,462USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2013-01-01 to 2013-06-300USD181
2002-11-07 to 2013-06-3031,667USD3889
2012-01-01 to 2012-06-300USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-04-01 to 2013-06-301,648,838USD91
2013-01-01 to 2013-06-303,239,450USD181
2002-11-07 to 2013-06-3029,167,175USD3889
2012-04-01 to 2012-06-301,314,623USD91
2012-01-01 to 2012-06-302,642,937USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-06-3057,397,997shares
At 2012-12-3146,397,997shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-06-3051,239,102USD
At 2012-12-3150,435,311USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2013-06-3027,222USD
At 2012-12-3127,222USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2013-06-30147,369USD
At 2012-12-31327,393USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2013-04-01 to 2013-06-30-2,064,462USD91
2013-01-01 to 2013-06-30-5,518,341USD181
2002-11-07 to 2013-06-30-46,339,100USD3889
2012-04-01 to 2012-06-30-2,230,811USD91
2012-01-01 to 2012-06-30-4,587,714USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-04-01 to 2013-06-301,073,749USD91
2013-01-01 to 2013-06-302,195,452USD181
2002-11-07 to 2013-06-3015,490,162USD3889
2012-04-01 to 2012-06-30896,881USD91
2012-01-01 to 2012-06-301,894,552USD182

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2013-01-01 to 2013-06-30219,968USD181
2002-11-07 to 2013-06-303,133,259USD3889
2012-01-01 to 2012-06-30266,077USD182

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2013-04-01 to 2013-06-300USD91
2013-01-01 to 2013-06-300USD181
2002-11-07 to 2013-06-301,161USD3889
2012-04-01 to 2012-06-300USD91
2012-01-01 to 2012-06-300USD182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2013-04-01 to 2013-06-30658,125USD91
2013-01-01 to 2013-06-30-83,439USD181
2002-11-07 to 2013-06-30-339,271USD3889
2012-04-01 to 2012-06-30-19,307USD91
2012-01-01 to 2012-06-30-50,225USD182

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2013-01-01 to 2013-06-304,975,153USD181
2002-11-07 to 2013-06-3043,688,181USD3889
2012-01-01 to 2012-06-304,870,978USD182

Inspect the source

Entity
Cellectar Biosciences, Inc. / CIK 0001279704
Captured
2026-09-20T07:48:31.991Z
SEC response SHA-256
44da00fed89c835867d9290b98319109f07ad849957763fd081353f99891a212

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001279704.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))